Estimates Revisions Takeda Pharmaceutical Company Limited Mexican S.E.
Stocks
TAK N
US8740602052
Pharmaceuticals
|
End-of-day quote
Mexican S.E.
2026-03-25
|
5-day change | 1st Jan Change | ||
| 320.00 MXN | +41.59% |
|
-.--% | +21.86% |
| 09-30 | Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading | MT |
| 09-30 | Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Takeda Pharmaceutical Company Limited(4502)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Takeda Pharmaceutical Company Limited(4502)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Takeda Pharmaceutical Company Limited(4502)
EBIT
Dividend / Share (DPS)
Data source:
Takeda Pharmaceutical Company Limited(4502)
Cash or Net Debt
Select your edition
All financial news and data tailored to specific country editions
